广州蒽恺赛生物科技

Guangzhou NKS Biotechnology is a clinical-stage biopharmaceutical company focused on the development of Natural Killer (NK) cell-based immunotherapies for the treatment of solid tumors and hematological malignancies. The company leverages its proprietary NK cell expansion and activation technology to produce high-purity, high-activity off-the-shelf cell therapy products. Its lead candidate, NKS01, is currently in clinical trials for advanced hepatocellular carcinoma, demonstrating the company's commitment to addressing unmet needs in oncology. NKS Biotechnology's platform aims to overcome the limitations of current cell therapies by improving cell persistence and infiltration into solid tumor tissues. The firm is headquartered in the Guangzhou International Bio Island, a major hub for biotech innovation in China. By utilizing allogeneic sources, the company seeks to reduce the cost and complexity associated with personalized cell treatments.